PhRMA Disputes Use Of Compulsory License To Ease Drug Shortages In India
This article was originally published in PharmAsia News
Inadequate Infrastructure is acutely evident in India, and the prime reason for the country’s poor healthcare system, says the trade body.
You may also be interested in...
FDA is allowing Sun Pharma Global FZE to import its unapproved liposomal version of doxorubicin, Lipodox, to alleviate a shortage, but has not yet given the drug full approval.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.